[Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC]

Area of Science:

• Oncology
• Neurology
• Immunology

Background:

• Brain metastases (BM) are a frequent and severe complication of non-small cell lung cancer (NSCLC).
• BM significantly contributes to disability and mortality in advanced NSCLC patients.
• The unique tumor microenvironment of NSCLC BM influences treatment efficacy.

Purpose of the Study:

• To review recent advancements in treating NSCLC BM.
• To explore the role of targeted therapies and immunotherapies.
• To provide insights into combination strategies and novel immunotherapeutic approaches for NSCLC BM.

Main Methods:

• Literature review of recent research on NSCLC BM treatments.
• Analysis of targeted therapies, including tyrosine kinase inhibitors.
• Evaluation of immunotherapy, focusing on PD-1/PD-L1 inhibitors and combination therapies.

Main Results:

• Small-molecule tyrosine kinase inhibitors are effective for NSCLC BM with driver gene mutations.
• Immunotherapy, particularly PD-1/PD-L1 inhibitors, is a key option for patients without classic oncogene addiction.
• Biomarker roles in NSCLC BM treatment are becoming increasingly significant.

Conclusions:

• Combination strategies integrating targeted therapy and immunotherapy show promise for NSCLC BM.
• Understanding the immunopathology of the brain metastasis microenvironment is crucial for developing novel treatments.
• Further research is needed to optimize therapeutic approaches and develop new immunotherapies for NSCLC BM.